Design and rationale for the prospective treatment efficacy in IPF using genotype for NAC selection (PRECISIONS) clinical trial.

BMC Pulm Med · 2022 · PMC9746571 · PMID 36514019

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

In contrast, participants with the TOLLIP CC genotype (about 25% of the cohort) showed a trend toward harm from NAC treatment.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.